創薬市場：薬剤タイプ、技術、治療領域、エンドユーザー別-2023-2030年の世界予測

創薬市場規模は2022年に547億4,000万米ドルと推計され、2023年には623億8,000万米ドルに達し、CAGR 14.08%で2030年には1,571億3,000万米ドルに達すると予測されます。

世界の創薬市場

創薬は、新規化合物の同定、その生物学的標的の解明、疾患治療への可能性の決定を包含する多面的で複雑なプロセスです。このプロセスは新薬開発の基本であり、生物学、化学、薬理学、医学など様々な分野の科学者が協力して取り組む必要があります。製薬・バイオ医薬品業界における研究開発（R&D）支出の増加や、新興国市場の開発に対する政府の支援は、市場の成長を後押ししています。また、前臨床試験中に生成される大量のデータを管理する必要性が高まっていることも、市場の成長を後押ししています。創薬と市場開拓のための巨額の資本が必要であり、創薬における動物使用に関する厳しい規範が市場成長の妨げとなっています。創薬における技術の進歩と革新、および創薬への合理化された自動化されたアプローチを作成するためのAIクラウドの使用の増加は、創薬の大幅な成長のための態勢を整えると予想されます。

地域別インサイト

南北アメリカは、研究開発への多額の投資、製薬大手の存在感、規制環境の整備など、強固な創薬インフラを象徴しています。ヘルスケアインフラへの投資が増加し、地域の健康問題に対応するための医療イノベーションの必要性が高まっていることが、南北アメリカにおける創薬ソリューションの必要性を加速させています。欧州では、先進的なヘルスケアシステム、政府および民間からの多額の資金援助、イノベーションと各国間のコラボレーションへの強い注目が、創薬へのニーズに拍車をかけています。中東・アフリカでは、医療支出の増加や地域の製薬産業育成に向けた取り組みにより、ニーズが高まっています。アジア太平洋地域は、人口の多さ、経済的繁栄の増大、ヘルスケア・インフラの改善、医療意識の高まり、バイオテクノロジーと製薬セクターを支援する政府のイニシアティブにより、創薬市場の重要なプレーヤーとして急速に台頭しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、創薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、創薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-創薬市場の市場規模および予測は？

2-創薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-創薬市場における技術動向と規制の枠組みは？

4-創薬市場における主要ベンダーの市場シェアは？

5-創薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬およびバイオ医薬品業界における研究開発費の増加
    • 前臨床研究中に生成される大量のデータを管理する必要性の増大
    • 創薬プラットフォームの開発に対する政府の好意的な支援
  • 抑制要因
    • 創薬と開発には多額の資本が必要
  • 機会
    • 創薬における技術の進歩と革新
    • AIクラウドを使用して創薬で合理化および自動化されたアプローチを作成する
  • 課題
    • 創薬の動物使用に関する厳格な規範
• 市場セグメンテーション分析
  • 薬剤の種類：ブランド製品とジェネリック製品による低分子薬剤のニーズの高まり
  • テクノロジー：生物分析機器の利用の拡大と、創薬の初期段階でのハイスループットスクリーニング
  • 治療分野：腫瘍治療薬の開発における創薬のニーズの高まり
  • エンドユーザー：新薬や改良薬の開発のために製薬会社やバイオテクノロジー会社全体で創薬の使用が増加
• 市場動向分析
  • 南北アメリカでは先進的かつ革新的な創薬テクノロジーが好まれます
  • アジア太平洋全体で臨床試験の数が急増し、医薬品開発に対する税制上の優遇措置が受けられる
  • 創薬とEMEA地域の開発に対する政府の支援と取り組み
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み

第6章 創薬市場薬剤の種類別

• 生物学的製剤
• 低分子薬

第7章 創薬市場：技術別

• 生物分析機器
• バイオチップ
• バイオインフォマティクス
• コンビナトリアルケミストリー
• ハイスループットスクリーニング
• ナノテクノロジー
• 薬理ゲノミクス

第8章 創薬市場治療領域別

• 循環器疾患
• 消化器系の病気
• 感染症と免疫系の病気
• 神経内科
• 腫瘍学

第9章 創薬市場：エンドユーザー別

• 学術調査機関
• 受託調査機関
• 製薬会社

第10章 南北アメリカの創薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の創薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの創薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ主要企業別の分析
  • 合併・買収
  • 契約、コラボレーション、パートナーシップ
  • 新製品発売と機能強化
  • 投資、資金調達
  • 受賞・表彰・拡大

第14章 競争力のあるポートフォリオ

• 主要な企業プロファイル
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • Astrazeneca PLC
  • Atomwise, Inc.
  • BenevolentAI
  • Bio-Rad Laboratories, Inc.
  • BioSymetrics Inc.
  • Charles River Laboratories International, Inc.
  • Chembridge Corporation
  • Cloud Pharmaceuticals, Inc.
  • Dalriada Drug Discovery
  • Deciphera Pharmaceuticals, Inc.
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • GENFIT SA
  • Incyte Corporation
  • International Business Machines Corporation
  • Intra-Cellular Therapies Inc.
  • Merck KGaA
  • Microsoft Corporation
  • NVIDIA Corporation
  • PerkinElmer, Inc.
  • Pharmacelera SL
  • Piramal Group
  • Recursion Pharmaceuticals, Inc.
  • Schrodinger, Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
• 主要な製品ポートフォリオ

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. DRUG DISCOVERY MARKET RESEARCH PROCESS
• FIGURE 2. DRUG DISCOVERY MARKET SIZE, 2022 VS 2030
• FIGURE 3. DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. DRUG DISCOVERY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 5. DRUG DISCOVERY MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 6. DRUG DISCOVERY MARKET DYNAMICS
• FIGURE 7. DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
• FIGURE 8. DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
• FIGURE 10. DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2030 (%)
• FIGURE 12. DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. DRUG DISCOVERY MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 14. DRUG DISCOVERY MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 16. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
• FIGURE 18. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 23. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 24. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 6. DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 9. DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 17. DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. DRUG DISCOVERY MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 42. CANADA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 64. CHINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 68. INDIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 137. ITALY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. POLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 153. POLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. QATAR DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 157. QATAR DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 195. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 196. DRUG DISCOVERY MARKET LICENSE & PRICING

[187 Pages Report] The Drug Discovery Market size was estimated at USD 54.74 billion in 2022 and expected to reach USD 62.38 billion in 2023, at a CAGR 14.08% to reach USD 157.13 billion by 2030.

Global Drug Discovery Market

Drug discovery is a multifaceted and intricate process that encompasses the identification of novel compounds, the elucidation of their biological targets, and the determination of their therapeutic potential for the treatment of diseases. This process is fundamental to developing new medicines and involves a collaborative effort among scientists from various disciplines, including biology, chemistry, pharmacology, and medicine. Rising research and development (R&D) expenditure in the pharmaceutical and biopharmaceutical industry and favorable government support for developing drug discovery platforms are propelling the market growth. In addition, the increasing need to manage large amounts of data generated during preclinical studies is fueling market growth. The necessity of extensive capital for drug discovery and development and stringent norms for animal usage in drug discovery are hampering market growth. Technological advancements and innovations in drug discovery and the growing use of AI cloud to create a streamlined and automated approach to drug discovery are expected to be poised for significant growth in drug discovery.

Regional Insights

Americas represents a robust drug discovery infrastructure with significant investments in R&D, a strong presence of pharmaceutical giants, and a conducive regulatory environment. Increasing investment in healthcare infrastructure and growing need for medical innovation to address local health concerns are accelerating the need for drug discovery solutions in the Americas. In Europe, the need for drug discovery is fueled by advanced healthcare systems, substantial government and private funding, and a strong focus on innovation and collaboration across countries. The Middle East and Africa exhibit growing need, with increased healthcare spending and initiatives to foster local pharmaceutical industries. The Asia-Pacific region is rapidly emerging as a significant player in the drug discovery market due to its large population, increasing economic prosperity, improvements in healthcare infrastructure, rising healthcare awareness, and government initiatives to support the biotechnology and pharmaceutical sectors.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug Discovery Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug Discovery Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Evotec SE, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Type
  • Biologic Drugs
  • Small Molecule Drugs
• Technology
  • Bioanalytical Instruments
  • Biochips
  • Bioinformatics
  • Combinatorial Chemistry
  • High Throughput Screening
  • Nanotechnology
  • Pharmacogenomics
• Therapeutic Area
  • Cardiovascular Disease
  • Digestive System Diseases
  • Infectious & Immune system Diseases
  • Neurology
  • Oncology
• End User
  • Academics & Research Institutes
  • Contract Research Organizations
  • Pharmaceutical Companies
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Georgia
      • Illinois
      • Indiana
      • Michigan
      • New York
      • North Carolina
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Drug Discovery Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug Discovery Market?

3. What are the technology trends and regulatory frameworks in the Drug Discovery Market?

4. What is the market share of the leading vendors in the Drug Discovery Market?

5. Which modes and strategic moves are suitable for entering the Drug Discovery Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Drug Discovery Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising R&D Expenditure in the Pharmaceutical & Biopharmaceutical industry
    • 5.1.1.2. Increasing Need to Manage Large Data Generated During Preclinical Studies
    • 5.1.1.3. Favorable Government Support For the Development of Drug Discovery Platforms
  • 5.1.2. Restraints
    • 5.1.2.1. Requirement of Extensive Capital for Drug Discovery and Development
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological Advancements and Innovations in Drug Discovery
    • 5.1.3.2. Use of AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Norms for the Animal Usage in Drug Discovery
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
  • 5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
  • 5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
  • 5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
• 5.3. Market Trend Analysis
  • 5.3.1. Preference for advanced and innovative drug discovery technologies in the Americas
  • 5.3.2. Proliferating number of clinical trials and availability of tax-incentives for drug development across the Asia-Pacific
  • 5.3.3. Supportive government funding and initiatives for drug discovery and development in the EMEA region
• 5.4. Cumulative Impact of COVID-19
• 5.5. Cumulative Impact of Russia-Ukraine Conflict
• 5.6. Cumulative Impact of High Inflation
• 5.7. Porter's Five Forces Analysis
  • 5.7.1. Threat of New Entrants
  • 5.7.2. Threat of Substitutes
  • 5.7.3. Bargaining Power of Customers
  • 5.7.4. Bargaining Power of Suppliers
  • 5.7.5. Industry Rivalry
• 5.8. Value Chain & Critical Path Analysis
• 5.9. Regulatory Framework

6. Drug Discovery Market, by Drug Type

• 6.1. Introduction
• 6.2. Biologic Drugs
• 6.3. Small Molecule Drugs

7. Drug Discovery Market, by Technology

• 7.1. Introduction
• 7.2. Bioanalytical Instruments
• 7.3. Biochips
• 7.4. Bioinformatics
• 7.5. Combinatorial Chemistry
• 7.6. High Throughput Screening
• 7.7. Nanotechnology
• 7.8. Pharmacogenomics

8. Drug Discovery Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular Disease
• 8.3. Digestive System Diseases
• 8.4. Infectious & Immune system Diseases
• 8.5. Neurology
• 8.6. Oncology

9. Drug Discovery Market, by End User

• 9.1. Introduction
• 9.2. Academics & Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical Companies

10. Americas Drug Discovery Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Drug Discovery Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player
  • 13.3.1. Merger & Acquisition
    • 13.3.1.1. Recursion Plans USD 87.5m Acquisitions To Shore Up AI Drug Discovery
    • 13.3.1.2. Eurofins Discovery Acquires CALIXAR, Expanding Integrated Drug Discovery Capabilities and Expertise
  • 13.3.2. Agreement, Collaboration, & Partnership
    • 13.3.2.1. Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
    • 13.3.2.2. IGC Pharma signs agreement to adopt AI solutions into drug discovery
    • 13.3.2.3. University of Tsukuba and Astellas Confirm a Strategic Partnership
    • 13.3.2.4. Sosei and PharmEnable collaborate on another neurological drug
    • 13.3.2.5. Novo Nordisk and Evotec launch translational drug discovery accelerator
  • 13.3.3. New Product Launch & Enhancement
    • 13.3.3.1. Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development
    • 13.3.3.2. Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
    • 13.3.3.3. PerkinElmer Unveils Multimode Plate Reader To Expedite Drug Discovery
  • 13.3.4. Investment & Funding
    • 13.3.4.1. Mestastop Raises USD 500k To Further Its Cancer Drug Discovery
    • 13.3.4.2. Genesis Raises USD 200 Million For AI Drug Discovery Research
    • 13.3.4.3. BenchSci Raises USD 95 Million Series D Funding to Enable Drug Discovery Innovation at Scale With its Groundbreaking AI Platform ASCEND
  • 13.3.5. Award, Recognition, & Expansion
    • 13.3.5.1. LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA
    • 13.3.5.2. Incyte Announces FDA Approval Of Pemazyre (Pemigatinib) As Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

14. Competitive Portfolio

• 14.1. Key Company Profiles
  • 14.1.1. Abbott Laboratories
  • 14.1.2. Agilent Technologies, Inc.
  • 14.1.3. Alacrita Holdings Limited
  • 14.1.4. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • 14.1.5. Astrazeneca PLC
  • 14.1.6. Atomwise, Inc.
  • 14.1.7. BenevolentAI
  • 14.1.8. Bio-Rad Laboratories, Inc.
  • 14.1.9. BioSymetrics Inc.
  • 14.1.10. Charles River Laboratories International, Inc.
  • 14.1.11. Chembridge Corporation
  • 14.1.12. Cloud Pharmaceuticals, Inc.
  • 14.1.13. Dalriada Drug Discovery
  • 14.1.14. Deciphera Pharmaceuticals, Inc.
  • 14.1.15. Evotec SE
  • 14.1.16. F. Hoffmann-La Roche Ltd.
  • 14.1.17. GENFIT SA
  • 14.1.18. Incyte Corporation
  • 14.1.19. International Business Machines Corporation
  • 14.1.20. Intra-Cellular Therapies Inc.
  • 14.1.21. Merck KGaA
  • 14.1.22. Microsoft Corporation
  • 14.1.23. NVIDIA Corporation
  • 14.1.24. PerkinElmer, Inc.
  • 14.1.25. Pharmacelera SL
  • 14.1.26. Piramal Group
  • 14.1.27. Recursion Pharmaceuticals, Inc.
  • 14.1.28. Schrodinger, Inc.
  • 14.1.29. Shimadzu Corporation
  • 14.1.30. Thermo Fisher Scientific Inc.
• 14.2. Key Product Portfolio

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing